Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, will provide a corporate update at the 2026 Jefferies Global Healthcare Conference. The presentation will highlight progress on telitacicept, their novel dual-target fusion protein currently in Phase 3 clinical development.